SCHEMBL7187136

SCHEMBL7187136

CCO[PH](=O)OC(C(=O)c1c(C)cc(C)c(C)c1C)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 6/20 0.37
LMNA P02545 3/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
ALDH1A1 P00352 2/20 0.36
PPARG P37231 4/20 0.35
NPSR1 Q6W5P4 2/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ADRB2 P07550 1/20 0.33
MMP8 P22894 1/20 0.33
F2 P00734 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183300 0.88 MEN1 (0.41) PPARALMNAGAAHTTALDH1A1
SCHEMBL7181525 0.85 L3MBTL1 (0.40) PPARALMNAALDH1A1PPARGNPSR1
SCHEMBL7735682 0.85 PPARA (0.36) PPARALMNAGAAHTTALDH1A1
SCHEMBL7177113 0.80 MAPT (0.37) PPARALMNAGAAALDH1A1PPARG
SCHEMBL7183743 0.79 PPARA (0.38) PPARALMNAALDH1A1PPARGCYP3A4
SCHEMBL7181329 0.78 CA12 (0.42) PPARALMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL7181130 0.78 TDP1 (0.39) CYP3A4MEN1KMT2A
SCHEMBL7187009 0.76 PPARG (0.35) PPARAALDH1A1PPARGCYP1A2CYP3A4
SCHEMBL7176038 0.74 ALDH1A1 (0.39) PPARALMNAALDH1A1NPSR1MEN1
SCHEMBL7189306 0.73 MMP8 (0.51) GAASMN1; SMN2MEN1KMT2AMMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 PPARA 3039/4885LMNA 3241/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 PPARA 2624/4885LMNA 3247/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.